CoChat
Sign Up
Cited by 520

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

De Martin, Eleonora, Michot, Jean-Marie, Papouin, Barbara, Champiat, Stéphane, Mateus, Christine, Lambotte, Olivier, Roche, Bruno, Antonini, Teresa Maria, Coilly, Audrey, Laghouati, Salim, Robert, Caroline, Marabelle, Aurélien, Guettier, Catherine, Samuel, Didier·2018·Journal of Hepatology
DOI 10.1016/j.jhep.2018.01.033
Open this paper in CoChat — free account

Abstract

Background & aims Immunotherapy for metastatic cancer can be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) monoclonal antibodies (mAbs). Methods Among 536 patients treated with anti-PD-1/PD-L1 or CTLA-4 immunotherapies, 19 (3.5%) were referred to the liver unit for grade ≥3 hepatitis. Of these patients, nine had received anti-PD-1/PD-L1 and seven had received anti-CTLA-4 mAbs, in monotherapy or in combination with anti-PD-1. Liver investigations were undertaken in these 16 patients, including viral assays, autoimmune tests and liver biopsy, histological review, and immunostaining of liver specimens. Results In the 16 patients included in this study, median age was 63 (range 33-84) years, and nine (56%) were female. Time between therapy initiation and hepatitis was five (range, 1-49) weeks and median number of immunotherapy injections was two (range, 1-36). No patients developed hepatic failure. Histology related to anti-CTLA-4 mAbs demonstrated granulomatous hepatitis including fibrin ring granulomas and central vein endotheliitis. Histology related to anti-PD-1/PD-L1 mAbs was characterised by lobular hepatitis. The management of hepatic IRAEs was tailored according to the severity of both the biology and histology of liver injury: six patients improved spontaneously; seven received or…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.01.033

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. Hodi, 2016, Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, Lancet Oncol, 17, 1558, 10.1016/S1470-2045(16)30366-7 · DOI · Paper page
  2. Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 · DOI
  3. Pardoll, 2015, Cancer and the immune system: basic concepts and targets for intervention, Semin Oncol, 42, 523, 10.1053/j.seminoncol.2015.05.003 · DOI
  4. Michot, 2016, Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer, 54, 139, 10.1016/j.ejca.2015.11.016 · DOI · Paper page
  5. O'Day, 2010, Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study, Ann Oncol: Official J Eur Soc Med Oncol, 21, 1712, 10.1093/annonc/mdq013 · DOI
  6. Johncilla, 2015, Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases, Am J Surg Pathol, 39, 1075, 10.1097/PAS.0000000000000453 · DOI
  7. Spain, 2016, Management of toxicities of immune checkpoint inhibitors, Cancer Treat Rev, 44, 51, 10.1016/j.ctrv.2016.02.001 · DOI · Paper page
  8. Hofmann, 2016, Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 190, 10.1016/j.ejca.2016.02.025 · DOI
  9. Champiat, 2016, Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol: Official J Eur Soc Med Oncol, 27, 559, 10.1093/annonc/mdv623 · DOI · Paper page
  10. Fontana, 2014, Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives, Gastroenterology, 146, 914, 10.1053/j.gastro.2013.12.032 · DOI
  11. Fontana, 2016, The role of hepatitis E virus infection in adult Americans with acute liver failure, Hepatology, 64, 1870, 10.1002/hep.28649 · DOI
  12. Del Castillo, 2016, The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma, Clin Infect Dis: An official publication of the Infect Dis Soc Am, 63, 1490, 10.1093/cid/ciw539 · DOI
  13. Weber, 2016, Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial, Lancet Oncol, 17, 943, 10.1016/S1470-2045(16)30126-7 · DOI
  14. Zhang, 2016, Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis, Drug Des Devel Ther, 10, 3153, 10.2147/DDDT.S115493 · DOI
  15. Ribas, 2013, Hepatotoxicity with combination of vemurafenib and ipilimumab, N Engl J Med, 368, 1365, 10.1056/NEJMc1302338 · DOI
  16. Spengler, 2017, Vemurafenib-induced granulomatous hepatitis, Hepatology, 65, 745, 10.1002/hep.28692 · DOI
  17. Murphy, 2014, New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment, Oncol Res Treat, 37, 351, 10.1159/000362614 · DOI
  18. Andersen, 2014, Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab, Oncoimmunology, 3, e954506, 10.4161/21624011.2014.954506 · DOI
  19. Berthod, 2012, Pulmonary sarcoid-like granulomatosis induced by ipilimumab, J Clin Oncol: Official J Am Soc Clin Oncol, 30, e156, 10.1200/JCO.2011.39.3298 · DOI
  20. Everett, 2017, Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis, Am J Surg Pathol, 41, 134, 10.1097/PAS.0000000000000759 · DOI
  21. Simonelli, 2016, Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma, Immunotherapy, 8, 1363, 10.2217/imt-2016-0057 · DOI
  22. Ziemer, 2017, Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids, J Hepatol, 66, 657, 10.1016/j.jhep.2016.11.015 · DOI
  23. Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 26, 2375, 10.1093/annonc/mdv383 · DOI
  24. Chmiel, 2011, Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy, J Clin Oncol: Official J Am Soc Clin Oncol, 29, e237, 10.1200/JCO.2010.32.2206 · DOI
  25. Indini, 2016, Immune suppression and response to ipilimumab: assessing risk-to-benefit ratio, J Clin Oncol: Official J Am Soc Clin Oncol, 34, 1017, 10.1200/JCO.2015.65.0028 · DOI
  26. Downey, 2007, Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade, Clin Cancer Res: An official J Am Assoc Cancer Res, 13, 6681, 10.1158/1078-0432.CCR-07-0187 · DOI · Paper page
  27. Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan kettering cancer center, J Clin Oncol: Official J Am Soc Clin Oncol, 33, 3193, 10.1200/JCO.2015.60.8448 · DOI · Paper page
  28. Weber, 2015, Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.9018 · DOI

Cited by

Sorted by citations

Metadata

Authors
De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S., Robert, C., Marabelle, A., Guettier, C., & Samuel, D.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-06
Volume
68
Issue
6
Pages
1181-1190
ISSN
0168-8278
DOI
10.1016/j.jhep.2018.01.033
Cited by
520
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review